Lyme disease is a worrisome condition for both patients and clinicians. Patients have questions about symptoms, diagnosis, and the meaning of chronic Lyme disease. In laboratories, Borrelia burgdorferi is hard to culture, limiting our understanding of disease progression postinfection as well as interfering with our diagnostic abilities.
"Current tests for Lyme are good tests," says Elitza Theel, Director of Infectious Diseases Serology Laboratory at Mayo Clinic. But "they can miss initial infection." The problem, Theel explains, is that these tests look for antibodies; if the patient presents early in disease-say the first 2-4 weeks-the current tests can miss infection. Therefore, developing a new Lyme diagnostic that could catch disease earlier would be a powerful tool, not only for diagnosis, but also for understanding disease progression.
Past attempts to tackle these problems have focused on tests that optimize cell culture, says Theel, but since Borrelia burgdorferi is hard to grow and does not cause a huge bloodstream infection as bacteria do, these tools have not caught on. "PCR methods have been looked at, but sensitivity isn't strong because the organism doesn't reach a high enough concentration to become detectable," she says. Next-generation sequencing and microarray, with greater sensitivity for DNA and RNA, are currently in early stages of development for Lyme disease, says Theel. In this article, we focus on a third approach: a new class of tiny chemical biosensors that test directly for the bacteria itself, using standard antibody chemistry and carbon nanotubes for measuring charge changes.
What Is the Innovation?
"Detecting chemicals in medical diagnostics, or even out in environment, is something we are not very good at," says A.T. Charlie Johnson, a professor of physics and astronomy at the University of Pennsylvania. Johnson, who is also the Director of the Nanobiology Interface Center at the University of Pennsylvania, has his team working on nextgeneration nanochemical sensors, which are hybrids of nanomaterials and biomolecules. "Ten years ago, the question in my mind was, 'What can you do with a nanosystem?"' says Johnson. He says one obvious answer was advanced computing, but also floating in the air was the underdeveloped idea of chemical sensing. "Nanomaterials combined with biomolecules was a likely pathway that could potentially take us there" [to better developed chemical diagnostics], says Johnson. "We decided to look at chemical detection."
Decision in hand, Johnson became motivated to study the spirochete by a student in his laboratory whose entire family had Lyme disease. To build Lyme sensors, Johnson began attaching antibodies to carbon nanotube scaffolding "as a way to detect for protein from the Lyme organism itself," he says.
The first report on the work, a prototype using synthetic samples, was published in 2013 (1 ).
How Does It Work?
"We are targeting specific proteins known to be part of the Lyme organism, and that we believe are not likely to mutate," says Johnson. This includes the flagellar antigen p41. Johnson's sensor com-prises a monoclonal antibody covalently attached to a semiconductor field effect transistor (Fig. 1) . As an antigen binds, the surface-charge density on the field effect transistor changes, causing a shift in the threshold voltage, or the voltage at which conduction between the source and drain electrodes initiates in the transistor. According to Johnson, the beauty and simplicity of using a nanostructure is that each nanomaterial has its own specific electrostatic properties that are very sensitive to change. "Any nanomaterial is very sensitive to all the molecules or atoms in its environment," says Johnson. Thus the nanostructure has a baseline current reading that reflects the electrostatic environment. Once it is presented with a Lymeridden solution and the antigen binds to the antibody, the electrostatic environment changes, and the current through the nanomaterial changes immediately. By reading the output again, after the nanomaterial has been exposed to solution, Johnson's team can tell if bacteria are present.
"If looking for protein from Lyme, any amount in your body should be zero," says Johnson, "so if we see anything above the noise limit of the system, that says you are infected." The authors report a limit of detection of 1 ng/mL.
Where Can This Technology Fit in the Clinical Laboratory?
"There's not been great success before for an antigenbased Lyme test," says Theel. "This biosensor is the first one I've seen that shows some promise." But the devil is in the details. "Although I find the proof of concept interesting, I don't think it has the analytical sensitivity to become a meaningful clinical test," says Jason Park, Medical Director of the Advanced Diagnostics Laboratory at the Children's Medical Center Dallas. "In prior nanosensor studies, detection capabilities down to atto-[10 Ϫ18 ] grams per mL have been achieved," he says, sharing the report by Wujcik and colleagues (2 ) .
Johnson responds to Wujcik's review, "Without knowing more about the work in these particular references, it is hard to know how to respond. These are all very low limits of detection that stand far apart from the rest of the literature. Our most sensitive limits of detection involve measurements of liquid drops that contain on the order of an attomole of the target or even less." The thing is, no one quite knows what test sensitivity is needed, since the bacteria have eluded careful study. "We don't know at what concentration patients have infections," says Theel.
Determining whether the nanosensor becomes part of a clinician's armament will be based on an obvious first step: testing it on a clinical specimen. "Without a doubt an important challenge is to deal with human blood, which is basically filled with protein and other structures," says Johnson. "Looking for some small foreign protein in that very complicated background is not easy." "We need to know that it works in a complex matrix other than buffer," says Theel. "I was excited to read this, but was waiting to see the results in human samples."
In their paper, Johnson's team reports that tests using bovine serum albumin at high concentration "to approximate the effect of non-specific proteins present in patient samples" showed preliminary success (1 ). Theel suggests that if blood proves too complicated, the team might look at other fluid targets, such as urine or spinal fluid, since Lyme affects the central nervous system. Johnson also talks of moving beyond p41, imagining a biosensor that is multipronged, testing for a handful of Lyme-specific antigens to enhance specificity as well as add redundancy (to prevent false positives).
Park suspects reagent antibodies, such as those Johnson is employing, are one of the ways forward for understanding Lyme disease. "I would speculate that future direct testing methods that exceed the sensitivity of conventional PCR may be able to detect Borrelia burgdorferi prior to a patient developing antibodies," he says. "I foresee that high sensitivity detection of antigens will continue to need reagent antibodies for capture and/or detection."
As the test stares down each upcoming hurdle, our experts suggest it will not just be Lyme disease specialists who will be paying attention. "This innovation could work for any organism we have difficulty isolating," says Theel, identifying Treponema pallidum (which causes syphilis) and Leptospira as 2 possible benefactors. And what if this works? "The gates are open," she says. Maybe even for biomarkers such as those for cancer.
And do not forget about the opportunities to learn more about the disease itself. Johnson, allowing himself for a moment to be swept into the possibility, not without some caution, laughs and notes, "If this works, this is disruptive." 
